Infectious keratitis is a major cause of blindness, next to cataract and majority of cases are mainly caused by gram negative bacterium Pseudomonas aeruginosa (P. aeruginosa). In this study, we investigated a P. aeruginosa VRFPA10 genome which exhibited susceptibility to commonly used drugs in vitro but the patient had poor prognosis due to its hyper virulent nature. Genomic analysis of VRFPA10 deciphered multiple virulence factors and P.aeruginosa Genomic Islands (PAGIs) VRFPA10 genome which correlated with hyper virulence nature of the organism. The 
Background
P.aeruginosa is the predominant gram negative bacterium often associated with ocular infections such as keratitis and scleritis. Scleritis is a severe painful condition caused by inflammatory process in the sclera, which may involve cornea, adjacent episclera and underlying uvea may turn into blindness condition [1] . In the current study, we investigated a 38 years old male patient with history of injury caused by foreign body and he was initially diagnosed and treated for perforated corneal ulcer. But, the patient subsequently developed into scleritis condition, despite appropriate medical management.
Materials and methods
The specimen was collected by an ophthalmologist as per standard method [2] . In brief, edge of the ulcer was firmly scraped using Bard Parker blade No. 15' after removal of debris or discharge in the vicinity. Several scrapings were collected and used in a sequence to inoculate culture media. Wherein, "C" curve on blood agar, MacConkey agar and inoculated on Brain Heart Infusion Broth (BHIB) initially. Upon confirmation of P.aeruginosa by biochemical methods, it was subcultured on Mueller Hinton agar plates to assess pigment production and was incubated at 37°C for 24 h.
After 24 h colonies greenish pigmented colonies morphologically resembling P. aeruginosa had grown in all the culture plates and identification was using a combination of colonial morphology with bluish [3, 4] . Further the organism was genotypically confirmed up to species level using 16s ribosomal RNA gene based sequencing result against blast tool available at NCBI database revealed 99% homology to all the existing P.aeruginosa strains in the database inclusive of our previously reported strains VRFPA01-VRFPA09 [5] [6] [7] [8] [9] [10] , hence the strain isolated from scleritis was designated as P.aeruginosa VRFPA10. Irrespective of the fact that P. aeruginosa VRFPA10 was phenotypically susceptible but the patient finally underwent Therapeutic Penetrating Keratoplasty (TPK). Whole genome study was undertaken by utilizing Ion Torrent (PGM) sequencer with 400-bp read chemistry (Life Technologies) accordance with manufacturer's instructions. In brief, genomic DNA from VRFPA10 was isolated from the overnight cultures with DNeasy miniprep kit (Qiagen, Hilden, Germany) and the sequencing protocol was followed as per previous study [5] [6] [7] [8] [9] [10] .
Genomic analysis
It is to be noted that there are no or scanty study available on Virulence factor and molecular mechanism of pathogenesis in P.aeruginosa mediated scleritis [11] [12] [13] [14] . Henceforth, we undertook this study to analyze VRFPA10 whole genome to unveil the genomic nature of virulence mechanism and drug resistance genes which may be involved in drug resistance in in vivo condition but may show susceptibility in in vitro tests.
Data of 56× coverage was produced after initial quality analysis and reference based assembly with P.aeruginosa VRFPA04 (CP008739.2) yielded 44 contigs with 7,728,786 bp (7.7 Mb genome size). The VRFPA10 genome was published in NCBI under the accession number LFMZ00000000.1. The genes were annotated by NCBI Prokaryotic Genomes Automatic Annotation Pipeline (PGAAP, http://www.ncbi.nlm. nih.gov/genomes/static/Pipeline.html). The genomic feature of VRFPA10 constitutes of 6431 genes and 5252 protein Coding Sequences (CDS). A total of 154 RNA encoding genes were identified, inclusive of 80 tRNA CDS, 73 rRNA CDS and 1 non-coding RNA encoding CDS. Multiple Locus Sequence Typing (MLST) analysis using Resfinder confirmed that VRFPA10 belongs to Sequence Type (ST)-313 reported by our group previously in VRFPA07 strain isolated from rectal swab of a different patient [6] .
Complete genomic analysis was carried out using CLC Genomics Workbench v 6.5.1. All available betalactamase, aminoglycosidase, Sul, CatB, TetG, dfrB, fosA and other resistant gene databases were downloaded from Resfinder [14] and it was installed in CLC Genomics Workbench as a complete database. Complete drug resistant database based blast analysis against VRFPA10 genome detected blaPA0, blaOXA-50, CatB7, FosA and OqxB (olaquindox resistant gene) [15] . Among the genes mentioned above, blaPA0 and blaOXA-50 were integrated into the chromosomal genome of all available P. aeruginosa genome which confers resistance to I and II generation cephalosporins and penicillin group of drugs. Whereas, CatB7, FosA and OqxB gene confers resistance to Chloramphenicol, Fosfomycin and olaquindox drugs respectively [16] . All the features were described in Table. 1
Blast analysis against various available virulence databases from NCBI unveiled the presence of Type 3 Secretion system (T3SS) cytotoxin encoding exoenzymes such as Exo-U, Exo-T, Exo-Y gene, Elastase B and ExotoxinA encoding genes among VRFPA10 genome [17] . These Exotoxin A and Elastase B are known to have an effect on ocular tissues, which may may have facilitated to adjacent episcleral invasion leading to scleritis condition. Furthermore, P.aeruginosa Genomic Islands (PAGI) otherwise called Region of Genomic Islands (RGPs) were identified among VRFPA10 genome which constituted PAGI-1,2,3,4 and 5, whereas no or partial trace of PAGI-6,7,8,9,10 was found scattered among VRFPA10 genome. This RGPs could have been obtained by Horizontal Gene Transfer (HGT) or phage infected genomes from various bacterial and viral sources that may be involved in inducing the pathogenicity of this VRFPA10 genome. These findings on VRFPA10 genome will aid in drug discovery against corneal virulence factor which may be helpful in treating the patient with corneal ulcers in addition to empirical drug regimens used in routine medical management. 
